BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 24149172)

  • 1. (18)F-FDG PET/CT surveillance at 3-6 and 12 months for detection of recurrence and second primary cancer in patients with head and neck squamous cell carcinoma.
    Kim JW; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Br J Cancer; 2013 Dec; 109(12):2973-9. PubMed ID: 24149172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.
    Suenaga Y; Kitajima K; Ishihara T; Sasaki R; Otsuki N; Nibu K; Minamikawa T; Kiyota N; Sugimura K
    Eur Radiol; 2016 Apr; 26(4):1018-30. PubMed ID: 26188656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDG PET/CT for detecting distant metastases in patients with recurrent head and neck squamous cell carcinoma.
    Yi JS; Kim JS; Lee JH; Choi SH; Nam SY; Kim SY; Roh JL
    J Surg Oncol; 2012 Nov; 106(6):708-12. PubMed ID: 22674652
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Kim SA; Roh JL; Kim JS; Lee JH; Lee SH; Choi SH; Nam SY; Kim SY
    Eur J Cancer; 2017 Feb; 72():62-70. PubMed ID: 28027517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative Contrast-Enhanced CT Versus ¹⁸F-FDG PET/CT Evaluation and the Prognostic Value of Extranodal Extension for Surgical Patients with Head and Neck Squamous Cell Carcinoma.
    Lee JR; Choi YJ; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1020-7. PubMed ID: 26122372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performance of FDG PET/CT to detect subclinical HNSCC recurrence 6 months after the end of treatment.
    Robin P; Abgral R; Valette G; Le Roux PY; Keromnes N; Rousset J; Potard G; Palard X; Marianowski R; Salaun PY
    Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):72-8. PubMed ID: 25169701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of subclinical recurrence or second primary cancer using (18) F-FDG PET/CT in patients treated curatively for head and neck squamous cell carcinoma.
    Kikuchi M; Shinohara S; Hino M; Itoh K; Tona R; Kishimoto I; Harada H; Fujiwara K; Suehiro A; Naito Y
    Head Neck; 2016 Apr; 38 Suppl 1():E511-8. PubMed ID: 25783743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective comparison of FDG and FET PET/CT in patients with head and neck squamous cell carcinoma.
    Balogova S; Périé S; Kerrou K; Grahek D; Montravers F; Angelard B; Susini B; El Chater P; St Guily JL; Talbot JN
    Mol Imaging Biol; 2008; 10(6):364-73. PubMed ID: 18668293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up?
    Abgral R; Querellou S; Potard G; Le Roux PY; Le Duc-Pennec A; Marianovski R; Pradier O; Bizais Y; Kraeber-Bodéré F; Salaun PY
    J Nucl Med; 2009 Jan; 50(1):24-9. PubMed ID: 19091901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body-MR imaging including DWIBS in the work-up of patients with head and neck squamous cell carcinoma: a feasibility study.
    Noij DP; Boerhout EJ; Pieters-van den Bos IC; Comans EF; Oprea-Lager D; Reinhard R; Hoekstra OS; de Bree R; de Graaf P; Castelijns JA
    Eur J Radiol; 2014 Jul; 83(7):1144-1151. PubMed ID: 24768188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of time-of-flight technique on the diagnostic performance of 18F-FDG PET/CT for assessment of lymph node metastases in head and neck squamous cell carcinoma.
    Li CY; Klohr S; Sadick H; Weiss C; Hoermann K; Schoenberg SO; Sadick M
    J Nucl Med Technol; 2014 Sep; 42(3):181-7. PubMed ID: 24970897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ¹⁸F-FDG-PET imaging in radiotherapy tumor volume delineation in treatment of head and neck cancer.
    Delouya G; Igidbashian L; Houle A; Bélair M; Boucher L; Cohade C; Beaulieu S; Filion EJ; Coulombe G; Hinse M; Martel C; Després P; Nguyen-Tan PF
    Radiother Oncol; 2011 Dec; 101(3):362-8. PubMed ID: 21885143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locoregional tumour evaluation of squamous cell carcinoma in the head and neck area: a comparison between MRI, PET/CT and integrated PET/MRI.
    Schaarschmidt BM; Heusch P; Buchbender C; Ruhlmann M; Bergmann C; Ruhlmann V; Schlamann M; Antoch G; Forsting M; Wetter A
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):92-102. PubMed ID: 26243264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F fluorodeoxyglucose PET/CT in head and neck squamous cell carcinoma with negative neck palpation findings: a prospective study.
    Roh JL; Park JP; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Radiology; 2014 Apr; 271(1):153-61. PubMed ID: 24475791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-fluoro-deoxy-glucose-positron emission tomography/computed tomography in diagnosis of head and neck squamous cell carcinoma: a systematic review and meta-analysis.
    Rohde M; Dyrvig AK; Johansen J; Sørensen JA; Gerke O; Nielsen AL; Høilund-Carlsen PF; Godballe C
    Eur J Cancer; 2014 Sep; 50(13):2271-9. PubMed ID: 25011659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement in the detection of locoregional recurrence in head and neck malignancies: F-18 fluorodeoxyglucose-positron emission tomography/computed tomography compared to high-resolution contrast-enhanced computed tomography and endoscopic examination.
    Rangaswamy B; Fardanesh MR; Genden EM; Park EE; Fatterpekar G; Patel Z; Kim J; Som PM; Kostakoglu L
    Laryngoscope; 2013 Nov; 123(11):2664-9. PubMed ID: 23553147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ¹⁸F-FDG PET/CT and MRI in the follow-up of head and neck squamous cell carcinoma.
    Ghanooni R; Delpierre I; Magremanne M; Vervaet C; Dumarey N; Remmelink M; Lacroix S; Trotta N; Hassid S; Goldman S
    Contrast Media Mol Imaging; 2011; 6(4):260-6. PubMed ID: 21861286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of outcomes with delayed (18)F-FDG PET-CT response assessment in head and neck squamous cell carcinoma.
    Slevin F; Subesinghe M; Ramasamy S; Sen M; Scarsbrook AF; Prestwich RJ
    Br J Radiol; 2015 Aug; 88(1052):20140592. PubMed ID: 26081447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
    Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
    Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.